{"id":"W4324136961","doi":"10.1200/jco.2023.41.6_suppl.lba16","title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Hazard ratio; Abiraterone acetate; Placebo; Progression-free survival; Interim analysis; Oncology; Prednisone; Confidence interval; Androgen deprivation therapy; Cancer; Surgery; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002300552,0.0007246244,0.001087544,0.000541034,0.0002088051,0.000756155,0.0007193222,0.0008909357,0.005584314],"category_scores_gemma":[0.001976585,0.0002961519,0.001502237,0.0003754524,0.0005707834,0.0009258752,0.0006295971,0.00199585,0.0004332],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009004184,"about_ca_system_score_gemma":0.001114485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004564031,"about_ca_topic_score_gemma":0.0014409,"domain_scores_codex":[0.99926,0.0003809331,0.00003760954,0.0001097568,0.00008941176,0.0001222251],"domain_scores_gemma":[0.9986771,0.0004382778,0.0004062616,0.00006978127,0.00006297242,0.000345695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.954173,0.002732344,0.002136181,0.0004800147,0.0007810427,0.00007574188,0.0000466428,0.001058882,0.004696046,0.0001064022,0.001194311,0.0325194],"study_design_scores_gemma":[0.4076948,0.5507306,0.02605227,0.0001973668,0.002135774,0.0003971754,0.0001004509,0.002608277,0.005635764,0.0006801399,0.003708069,0.00005935788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907929,0.004227088,0.0004036014,0.0002968572,0.0001400374,0.0005229089,0.00170512,0.00005254824,0.001858796],"genre_scores_gemma":[0.9939368,0.0009223396,0.0005655311,0.000254796,0.00009842127,0.0006982891,0.002045006,0.0000117781,0.001467038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005584314,"threshold_uncertainty_score":0.01868135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3104906633709295,"score_gpt":0.5159334548274083,"score_spread":0.2054427914564788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}